Mutations in the RAS-RAF-MEK-ERK pathway that drive many forms of human malignancies. In particular, the serine/threonine kinase BRAF is mutated in ~8% of all cancers. Targeted inhibitors have been ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...

The review explores strategies to overcome this resistance, focusing on targeting downstream molecules within the RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. Furthermore, the study explores the ...